Trial of PCSK9 Inhibition in Patients with Acute Stroke and Symptomatic Intracranial Atherosclerosis (TOPICAL-MRI)
Trial of PCSK9 Inhibition in Patients with Acute Stroke and Symptomatic Intracranial Atherosclerosis - a Prospective, Randomized, Open-label, Blinded End-point Study with High-resolution MR Vessel Wall Imaging
Sponsor: Chang Gung Memorial Hospital
This PHASE2 trial investigates Acute Ischemic Stroke and ICAS - Intracranial Atherosclerosis and is currently ongoing. Chang Gung Memorial Hospital leads this study, which shows 6 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Apr 2025 — Present [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Apr 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Recruiting PHASE2
-
Dec 2022 — Oct 2023 [monthly]
Recruiting PHASE2
▶ Show 1 earlier version
-
Sep 2021 — Dec 2022 [monthly]
Recruiting PHASE2
First recorded
Aug 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Chang Gung Memorial Hospital
- Chang Gung University
For direct contact, visit the study record on ClinicalTrials.gov .